Source Precision Medicine, Inc., dba SourceMDx Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. of the firm of Finn, Warnke & Gayton, LLP

WELLESLEY HILLS, Massachusetts, March 1, 2011 - Source Precision Medicine, Inc., dba SourceMDx ("SourceMDx") has assigned
all its assets to Joseph F. Finn, Jr., C.P.A. ("Finn") of the firm Finn,
Warnke & Gayton, LLP to be liquidated for the benefit of SourceMDx creditors.

Source MDx(R) is an industry leader in developing simple blood tests that
can consistently detect the presence and aggressiveness of cancer by
measuring specific RNA transcripts in blood. RNA is an early biological
measure of disease, providing a significant indicator of disease onset or
progression in the blood stream before other clinical manifestations become
observable. Source MDx(R) is the first to translate robust RNA-transcript
based assays into clinically useful oncology molecular diagnostic tests using
a simple, non-invasive blood test. Source MDx(R) tests are precise and
calibrated measurements of white blood cell gene expression and track an
individual's current health, disease status and response to therapy in a
reproducible fashion.

The intellectual property, patents, etc. will be sold at a sealed bid
sale on Friday, April 29, 2011 at noon.

Persons interested in bidding must sign a Confidentiality Disclosure
Agreement ("CDA") obtained from Finn's Office - jffinnjr@finnwarnkegayton.com
or +1-781-237-8840. They will then receive a bid package.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn,
Warnke & Gayton (www.finnwarnkegayton.com), Certified Public
Accountants of Wellesley Hills, Massachusetts. He works primarily in the area
of management consulting for distressed enterprises, bankruptcy accounting
and related matters, such as assignee for the benefit of creditors and
liquidating agent for a corporation. He has been involved in a number of loan
workouts and bankruptcy cases for thirty-five (35) years. His most recent
Assignments for the Benefit of Creditors in the biotech field include
Spherics, Inc., ActivBiotics, Inc., Prospect Therapeutics, Inc., EPIX
Pharmaceuticals Inc. and NoblePeak Vision Corp.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at
+1-781-237-8840 or jffinnjr@finnwarnkegayton.com

Joseph F. Finn, Jr., C.P.A., +1-781-237-8840, jffinnjr at finnwarnkegayton.com